Edwards Life Sciences up 4% after hours on strong Q3, guidance raise

Edwards Lifesciences (NYSE:EW) Q3 results:

Sales: $1,094.0M (+20.7%), TAVR: $700.0M (+25.7%); Surgical Structural Heart: $204.1M (+10.6%); Critical Care ex. CASMED: $174.7M (+6.4%).

Net income: $274.7M (+21.6%); non-GAAP net income: $299.2M (+31.2%); EPS: $1.30 (+22.6%); non-GAAP EPS: $1.41 (+31.8%).

2019 guidance: Sales: top end of previous range of $4.0B – 4.3B; non-GAAP EPS: $5.50 – 5.65 from $5.20 – 5.40.

https://seekingalpha.com/news/3508729-edwards-life-sciences-4-percent-hours-strong-q3-guidance-raise